| Novo Nordisk A/S ADR (NVO) | |||
|---|---|---|---|
| 126.85 1.06 (0.84%) | 04-26 16:00 | ||
| Open: | 126.15 | Pre. Close: | 125.79 |
| High: | 127.9 | Low: | 125.99 |
| Volume: | 3,209,299 | Market Cap: | 550,216(M) |
| Stock Technical Analysis | |
|---|---|
| Overall: |   |
| Target: | Six months: 152.13 One year: 177.69 |
| Support: | Support1: 125.02 Support2: 121.79 |
| Resistance: | Resistance1: 130.25 Resistance2: 152.13 |
| Pivot: | 125.15 |
| Moving Averages: | MA(5): 126.54 MA(20): 125.40  MA(100): 116.68 MA(250): 100.19 |
| MACD: | MACD(12,26): -0.16 Signal(12,26,9): -0.35 |
| %K %D: | %K(14,3): 64.23 %D(3): 69.64 |
| RSI: | RSI(14): 52.70 |
| 52-Week: | High: 138.28 Low: 75.56 Change(%): 51.8 |
| Average Vol(K): | 3-Month: 4868 10-Days: 3391 |
| Prices Prediction (Update @5:00pm) | ||
|---|---|---|
| If tomorrow: | Open lower | Open higher |
| High: | 127.964 - 128.595 | 128.595 - 129.234 |
| Low: | 124.494 - 125.154 | 125.154 - 125.822 |
| Close: | 125.797 - 126.835 | 126.835 - 127.886 |
| Price, MAs and Bollinger Bands |
|---|
| Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ NVO ] has closed below upper band by 23.6%. Bollinger Bands are 41.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend. |
| Company profile |
|---|
| Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark. |
| Stock chart |
|---|
 |
| Financial Analysis | |
|---|---|
| Price to Book Value: | Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. | |
| Price to Earnings: | Outperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). | |
| Discounted cash flow: | Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. | |
| Return on Assets: | Outperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. | |
| Return on Equity: | Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. | |
| Debt to Equity: | Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. | |
| Stock Basics & Statistics | |
|---|---|
| Exchange: New York Stock Exchange | |
| Sector: Healthcare | |
| Industry: Biotechnology | |
| Shares Out. (M) | 4460.00 |
| Shares Float (M) | 3190.00 |
| % Held by Insiders | |
| % Held by Institutions | 9.32 |
| Shares Short (K) | 2830 |
| Shares Short Prior Month (K) | 4880 |
| Stock Financials | |
|---|---|
| EPS | 2.660 |
| Book Value (p.s.) | 23.900 |
| Profit Margin | 36.03 |
| Operating Margin | 42.79 |
| Return on Assets (ttm) | 23.4 |
| Return on Equity (ttm) | 88.1 |
| Qtrly Rev. Growth | 37.0 |
| Gross Profit (p.s.) | |
| Sales Per Share | 52.076 |
| EBITDA (p.s.) | 24.621 |
| Qtrly Earnings Growth | 63.10 |
| Operating Cash Flow (M) | 108910.00 |
| Levered Free Cash Flow (M) | 54100.00 |
| Stock Valuation | |
|---|---|
| PE Ratio | 47.69 |
| PEG Ratio | 92.28 |
| Price to Book value | 5.31 |
| Price to Sales | 2.43 |
| Price to Cash Flow | 5.19 |
| Stock Dividends | |
|---|---|
| Dividend | |
| Dividend Yield | |
| Dividend Growth | |
